1
|
Sison-Young RLC, Mitsa D, Jenkins RE, Mottram D, Alexandre E, Richert L, Aerts H, Weaver RJ, Jones RP, Johann E, Hewitt PG, Ingelman-Sundberg M, Goldring CEP, Kitteringham NR, Park BK. Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication. Toxicol Sci 2015; 147:412-24. [PMID: 26160117 PMCID: PMC4583060 DOI: 10.1093/toxsci/kfv136] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
In vitro preclinical models for the assessment of drug-induced liver injury (DILI) are usually based on cryopreserved primary human hepatocytes (cPHH) or human hepatic tumor-derived cell lines; however, it is unclear how well such cell models reflect the normal function of liver cells. The physiological, pharmacological, and toxicological phenotyping of available cell-based systems is necessary in order to decide the testing purpose for which they are fit. We have therefore undertaken a global proteomic analysis of 3 human-derived hepatic cell lines (HepG2, Upcyte, and HepaRG) in comparison with cPHH with a focus on drug metabolizing enzymes and transport proteins (DMETs), as well as Nrf2-regulated proteins. In total, 4946 proteins were identified, of which 2722 proteins were common across all cell models, including 128 DMETs. Approximately 90% reduction in expression of cytochromes P450 was observed in HepG2 and Upcyte cells, and approximately 60% in HepaRG cells relative to cPHH. Drug transporter expression was also lower compared with cPHH with the exception of MRP3 and P-gp (MDR1) which appeared to be significantly expressed in HepaRG cells. In contrast, a high proportion of Nrf2-regulated proteins were more highly expressed in the cell lines compared with cPHH. The proteomic database derived here will provide a rational basis for the context-specific selection of the most appropriate ‘hepatocyte-like’ cell for the evaluation of particular cellular functions associated with DILI and, at the same time, assist in the construction of a testing paradigm which takes into account the in vivo disposition of a new drug.
Collapse
Affiliation(s)
- Rowena L C Sison-Young
- *Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, Liverpool L69 3GE, UK
| | - Dimitra Mitsa
- *Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, Liverpool L69 3GE, UK
| | - Rosalind E Jenkins
- *Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, Liverpool L69 3GE, UK
| | - David Mottram
- *Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, Liverpool L69 3GE, UK
| | | | | | - Hélène Aerts
- Biologie Servier, 905 Route de Saran, 45520, Gidy, France
| | | | - Robert P Jones
- *Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, Liverpool L69 3GE, UK
| | - Esther Johann
- North Western Hepatobiliary Unit, Aintree University Hospital NHS Foundation Trust, Longmoor Lane, Liverpool L9 7AL, UK
| | - Philip G Hewitt
- Merck KGaA, Merck Serono, Non-Clinical Safety, 64293 Darmstadt, Germany; and
| | - Magnus Ingelman-Sundberg
- Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE-17177 Stockholm, Sweden
| | - Christopher E P Goldring
- *Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, Liverpool L69 3GE, UK
| | - Neil R Kitteringham
- *Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, Liverpool L69 3GE, UK;
| | - B Kevin Park
- *Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, Liverpool L69 3GE, UK
| |
Collapse
|